802 related articles for article (PubMed ID: 31250218)
21. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
[TBL] [Abstract][Full Text] [Related]
23. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
Giannelos N; Ng C; Curran D
Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
26. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
27. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing.
Lee C; Jiang N; Tang H; Ye C; Yuan Y; Curran D
Hum Vaccin Immunother; 2021 Oct; 17(10):3735-3746. PubMed ID: 34310268
[TBL] [Abstract][Full Text] [Related]
28. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
Pieters Z; Ogunjimi B; Beutels P; Bilcke J
Pharmacoeconomics; 2022 Apr; 40(4):461-476. PubMed ID: 35094374
[TBL] [Abstract][Full Text] [Related]
30. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
31. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
32. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Sanford M; Keating GM
Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.
Teng L; Mizukami A; Ng C; Giannelos N; Curran D; Sato T; Lee C; Matsuki T
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1447-1467. PubMed ID: 35668295
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.
Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P
Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Rothberg MB; Virapongse A; Smith KJ
Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
[TBL] [Abstract][Full Text] [Related]
40. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]